Analysts expect that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will announce earnings per share (EPS) of $0.48 for the current quarter, Zacks reports. Five analysts have provided estimates for Endo International’s earnings, with the highest EPS estimate coming in at $0.51 and the lowest estimate coming in at $0.44. Endo International reported earnings per share of $0.95 in the same quarter last year, which would indicate a negative year over year growth rate of 49.5%. The company is expected to announce its next quarterly earnings report after the market closes on Thursday, May 6th.
On average, analysts expect that Endo International will report full-year earnings of $2.12 per share for the current financial year, with EPS estimates ranging from $1.95 to $2.28. For the next fiscal year, analysts forecast that the firm will report earnings of $2.11 per share, with EPS estimates ranging from $0.90 to $2.94. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, February 25th. The company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.27. The company had revenue of $760.22 million for the quarter, compared to the consensus estimate of $653.83 million. Endo International had a negative return on equity of 85.80% and a negative net margin of 5.30%. During the same quarter last year, the business posted $0.74 EPS.
ENDP traded down $0.38 during midday trading on Tuesday, hitting $5.49. 3,349,430 shares of the company were exchanged, compared to its average volume of 3,856,994. The firm has a market capitalization of $1.28 billion, a P/E ratio of -8.07 and a beta of 1.41. Endo International has a 1-year low of $2.71 and a 1-year high of $10.89. The firm’s 50 day moving average price is $6.89 and its 200-day moving average price is $6.73.
In other Endo International news, Director Shane Cooke sold 17,290 shares of the company’s stock in a transaction dated Monday, March 15th. The shares were sold at an average price of $8.65, for a total transaction of $149,558.50. Following the completion of the sale, the director now directly owns 97,104 shares in the company, valued at $839,949.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.50% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Carolina Wealth Advisors LLC boosted its holdings in shares of Endo International by 109.5% during the first quarter. Carolina Wealth Advisors LLC now owns 8,894 shares of the company’s stock worth $66,000 after purchasing an additional 4,648 shares during the period. Vantage Consulting Group Inc bought a new position in Endo International in the fourth quarter worth about $89,000. IFP Advisors Inc bought a new position in Endo International in the fourth quarter worth about $111,000. Nisa Investment Advisors LLC increased its stake in shares of Endo International by 131.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 17,700 shares of the company’s stock valued at $127,000 after purchasing an additional 10,050 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new position in shares of Endo International during the first quarter valued at approximately $235,000. Institutional investors own 79.98% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.
Featured Story: Outperform Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.